Recent news on Cerezyme

Genzyme's combination gene therapy shows potential for CNS disease  -  25 May 2007
DrugResearcher.com,Genzyme has invested heavily in gene therapy in the last few years and already has four products on the market: Cerezyme (imiglucerase for injection) for

Genzyme "buy," estimates raised  -  May 17, 2007
newratings.comGENZ '638 in Gaucher's disease was extremely compelling, and the drug might be used as a monotherapy, post an induction with Cerezyme, the analyst adds.

Genzyme to add 52 jobs at its biotechnology facility in Waterford ...  -  Apr 25, 2007
FinFacts Ireland,The new biologics fill-finish facility, which was completed in 2006, currently produces Thymoglobulin, an anti-organ rejection agent and Cerezyme for the

Genzyme Reports Significant Revenue and Earnings Growth in First ...  -  Apr 25, 2007
MSN MoneySales of Cerezyme(R) (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, grew 10 percent to $263.8 million,

DR. WAXMAN'S DRUG LAB  -  Apr 10, 2007
National Center for Policy Analysis,Many biologics are breakthrough therapies, from Avastin, which chokes off the blood supply to cancerous tumors, to Cerezyme, which treats the rare genetic

Law Emerging in US for Generic Versions of Biotech Medicine  -  Apr 8, 2007
MedIndia,A year's worth of Genzyme's (DNA) Cerezyme, for a rare ailment called Gaucher's disease, can top $200000. Genentech's cancer drug Avastin costs as much as

Congress said to want cheaper biotech drugs  -  Apr 7, 2007
CNNMoney.comAvastin, a cancer treatment made by Genentech (Charts), can cost $4400 to $8800 a month while Cerezyme, a drug made by Genzyme (Charts) for Gaucher disease,

Adopting Profits  -  Apr 6, 2007
Drug Discovery & Development,Genzyme, for example, markets a drug called Cerezyme that treats Gaucher disease—a hereditary enzyme deficiency afflicting only around 10000 patients in the

Editorial: Orphan disease drugs  -  Apr 16, 2007
Bangor Daily News,Much attention has centered on Cerezyme, one of the most expensive of the biotech drugs. At an average price of $200000 a year, it can slow the course of

Congress Seeks Compromise on Generic Drugs  -  Apr 8, 2007
New York Times,Cerezyme, a drug made by Genzyme for Gaucher disease, costs $200000 a year. Enbrel, made by Amgen for rheumatoid arthritis and psoriasis, costs an average

Cashing in on 'orphans'  -  Mar 16, 2007
CNNMoney.comCerezyme, Genzyme's Gaucher drug, is one of the world's most expensive drugs. An annual supply can cost $200000. About 5000 patients take Cerezyme,

Cashing in on 'orphans'  -  Mar 15, 2007
CNNMoney.comCerezyme, Genzyme's Gaucher drug, is one of the world's most expensive drugs. An annual supply can cost $200000. Of the estimated 100000 Gaucher patients

Will Biological Drugs Go Generic?  -  Mar 14, 2007
BusinessWeekA year's worth of Genzyme's (DNA) Cerezyme, for a rare ailment called Gaucher's disease, can top $200000. Genentech's cancer drug Avastin costs as much as

William Blair & Company Initiates Coverage of Alexion ...  -  Mar 7, 2007
Business Wire (press release),...the lines of treatments for other rare genetic diseases—such as Cerezyme, to treat Gaucher disease—that command more than $200000 per year of treatment.

Drug Stock ABCs: Part 1  -  Feb 28, 2007
Motley FoolGenzyme (Nasdaq: GENZ) received orphan drug status on its enzyme replacement therapy Cerezyme back in 1994, when it was approved to treat the very rare

Genzyme Phasing in Annual Elections of Directors  -  Mar 1, 2007
PharmaLive.com (press release),Genzyme's first therapeutic program was a treatment for Gaucher disease, which ultimately developed into Cerezyme, the company's flagship product.

Genzyme Has Fourth-Quarter Loss; Sees Higher Sales (Update2)  -  Feb 14, 2007
BloombergFor the quarter, revenue rose 17 percent to $854.2 million, spurred by sales of Genzyme therapies for rare genetic disorders such as Cerezyme,

Genzyme posts strong financials, despite AnorMed charges  -  Feb 15, 2007
Pharma Times (subscription),Revenue rose 17% to $854.2 million, a record level, driven by sales of Gaucher disease treatment Cerezyme (imiglucerase), up 13% to $261.8 million and Fabry

TECHNOLOGY TRADER  -  Feb 18, 2007
Barron's (subscription)Sales in 2006 were $1 billion for the company's cash cow Cerezyme, which treats the genetic disorder Gaucher's disease. That was about a third of the firm's

Genzyme Reports Financial Results for Fourth Quarter of 2006 and ...  -  Feb 14, 2007
Oxfordshire Bioscience Network (press release),Sales of Cerezyme® (imiglucerase for injection) are expected to reach $1.060-$1.075 billion this year, compared with $1.0 billion in 2006.

GPhA Endorses Access to Life-Saving Medicine Act  -  Feb 18, 2007
Drug Newswire (press release),And Cerezyme, used to treat Gaucher disease, costs an average of $200000 per patient per year-with some adult patients paying more than $500000 a year.

Congress looks to give FDA authority to approve biogenerics  -  Feb 16, 2007
Pharma Times (subscription),It claims that treatment with Roche and Genentech's cancer drug Avastin (bevacizumab) costs $100000 per year, while Genzyme's Cerezyme (imiglucerase),

Legislation would allow generic biotech drugs in US  -  Feb 15, 2007
Budapest Business Journal,...s Cerezyme, a treatment for a rare enzyme disorder that can cost $200000 a year. Generic biotech medications could save sponsors of US health plans,

Zacks.com Announces That Nadine Wong Highlights: Genzyme  -  Feb 2, 2007
Business Wire (press release),Nadine Wong and her team anticipate a continued strong Myozyme launch, as well as solid Cerezyme and Fabrazyme sales performance.

Genzyme Announces Publication of Study Showing Impact of Cerezyme ...  -  Jan 16, 2007
Oxfordshire Bioscience Network (press release),Cerezyme, an enzyme replacement therapy, is the standard of care for patients with Type 1 Gaucher disease. Patients with Gaucher disease are at increased

Study show Genzyme's Cerezyme may be effective  -  Jan 15, 2007
Boston Business Journal,Genzyme Corp. is promoting results from a new clinical study that apparently validate long-term use of its enzyme replacement drug Cerezyme.

BioMarin Announces Positive Results from Phase 3 Diet Study of ...  -  Jan 17, 2007
Financial News USA (press release),...(Nasdaq: GENZ) is promoting results from a new clinical study that apparently validate long-term use of its enzyme replacement drug Cerezyme.

Genzyme drug helps bone in Gaucher disease  -  Jan 15, 2007
United Press International15 (UPI) -- US firm Genzyme said a new study shows its drug Cerezyme improves bone density in patients with type 1 Gaucher disease.

Drug study shows Genzyme's treatment to be effective  -  Jan 15, 2007
Worcester Business Journal,The study showed that Cerezyme helped improve bone mineral density in patients with Type 1 Gaucher disease in a dose-dependent manner.

Market Report -- In Play (WIRES)  -  Jan 16, 2007
MSN Money...that long-term use of Cerezyme significantly improves bone mineral density in patients with Type 1 Gaucher disease in a dose-dependent manner.

(PRN) - PA Game Commission: Pennsylvania Bears Denning in Winter ...  -  Jan 15, 2007
Bolsamania.com,...(PRN) - Genzyme Announces Publication of Study Showing Impact of Cerezyme on Bone Health for Patients With Type 1 Gaucher Disease ... [+]

Genzyme reports 17% jump in fourth-quarter revenue  -  Jan 9, 2007
MarketWatchSales of the company's top-selling drug Cerezyme were $262 million for the fourth quarter, up 13% from last year. Fabrazyme drug sales were up 18% from last

2006 in Review: Genzyme  -  Dec 29, 2006
Motley FoolSales were solid for all of its major products except Cerezyme (by far its biggest product, accounting for a third of sales). Cerezyme experienced markedly

Largest-ever Fabry study shows earlier treatment with (Pr ...  -  Jan 16, 2007
CNW Telbec (Communiqués de presse),These include Cerezyme(R) (imiglucerase) for the treatment of Type 1 and Type 3 Gaucher disease and Aldurazyme(R) (laronidase) for the treatment of MPS I,

Drugmakers want US to allow 'generic' biotech medicines  -  Jan 12, 2007
SalemNews.com,...s Cerezyme, a treatment for a rare enzyme disorder that can cost $200000 a year. General Motors Corp., the biggest US purchaser of health care outside the

Genzyme expects 2007 profit to rise on drug sales  -  Jan 9, 2007
Washington Post,Sales of the company's biggest drug, Cerezyme, a treatment for Gaucher disease, which causes enlargement of the liver and spleen, rose 13 percent to $262

Health Premium Hikes Tied to Costly Specialty Drugs  -  Dec 5, 2006
Insurance Journal,Studying Health System Change. One example of an expensive specialty drug is Cerezyme, made by Cambridge-based Genzyme Corp. It is used ...

Specialty drugs seen driving up premiums  -  Dec 4, 2006
Boston Globe,One specialty drug is Cerezyme , made by Genzyme Corp. and used to treat Gaucher disease. The genetic disorder causes enlarged internal ...

Genzyme Closes AnorMed Deal  09 Nov 2006
Genzyme has seen great success in treating rare illnesses and diseases: Cerezyme, its medication for the treatment of Gaucher disease, an enzyme deficiency ... -Red Herring, Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions (Update1)  Oct 12, 2006
Sales of the Genzyme's biggest seller, the Gaucher's disease drug Cerezyme, rose 5.8 percent. ... Cerezyme sales were $252.2 million in the quarter. ... -Bloomberg Genzyme Runs a Tight Ship  Oct 12, 2006
The one downside to the quarter is that sales growth for Genzyme's lead drug Cerezyme are still not picking up. Cerezyme sales only ... -Motley Fool Genzyme reports lower profit due to charges  Oct 12, 2006
Sales of the company's best-selling product, Cerezyme, a therapy for Type I Gaucher disease, increased 6% to $238.3 million over last year. ... -MarketWatch Genzyme 3Q Profit Fall 86 Percent  Oct 12, 2006
Sales of Gaucher disease treatment Cerezyme rose 6 percent to $252.2 million, and sales of kidney disease treatment Renagel grew 26 percent to $134.7 million ... -Houston Chronicle, Genzyme 3rd-qtr profit falls; charges offset sales  Oct 12, 2006
Sales of Cerezyme, the company's drug to treat Gaucher disease -- a condition that causes enlargement of the liver and spleen -- grew 6 percent to $252.2 ... -Reuters Genzyme 3rd-Quarter Profit Drops 86% on Acquisitions (Update4)  Oct 12, 2006
2005. Sales of Genzyme's biggest seller, Cerezyme for Gaucher's disease, rose 5.8 percent, accounting for about a third of revenue. ... -Bloomberg Genzyme`s Q3 fails to impress  Oct 12, 2006
Fabrazyme sales increased 18 percent to $93.2 million, Aldurazyme sales were up 24 percent to $25 million and Cerezyme sales rose 6 percent to $252 million. ... -Monsters and Critics.com, Novozymes raises earnings outlook after strong results  Oct 31, 2006
...projects in 2006. Cerezyme for example, an enzyme for brewing based on sorghum, was launched in the second quarter. And in August ... -LabTechnologist.com, Genzyme Reports Strong Third-Quarter Financial Results  Oct 12, 2006
Sales of Cerezyme® (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $252.2 million, 6 percent greater than sales of ... -Yahoo! News (press release) Genzyme's Sales Fall Short  Oct 12, 2006
Fabrazyme, a treatment for Fabry disease, saw sales rise 18% to $93.2 million, and revenue from Aldurazyme and Cerezyme totaled $25 million and $252.2 million ... -TheStreet.com Genzyme, Now In Front For AnorMED, Reports Earnings  Oct 13, 2006
Its top-selling drug was Cerezyme (imiglucerase), the enzyme-replacement therapy for Type I Gaucher's disease that generated $252.2 million in sales that were ... -BioWorld Online, Genzyme Shares Too Cheap To Ignore: Report  Sep 14, 2006
..."While emerging potential competition for Cerezyme/Fabrazyme will keep Genzyme's multiples below the group mean this year, we believe stock has upside ... -Forbes

Health Premium Hikes Tied to Costly Specialty Drugs  -  Dec 5, 2006
Insurance Journal,Studying Health System Change. One example of an expensive specialty drug is Cerezyme, made by Cambridge-based Genzyme Corp. It is used ...

Specialty drugs seen driving up premiums  -  Dec 4, 2006
Boston Globe,One specialty drug is Cerezyme , made by Genzyme Corp. and used to treat Gaucher disease. The genetic disorder causes enlarged internal ...

Genzyme given green light to make kidney drug at Irish plant  Aug 14, 2006
...months we expect to receive similar fill/finish approvals at the plant for two of our enzyme replacement therapies (ERT), Myozyme and Cerezyme,� said company ... -In-PharmaTechnologist.com

Shell Firm Acquiring Protalix, Phase III Gaucher's Therapy  Aug 22, 2006
...enzyme-shortage disease is glucocerebrosidase, which seeks to enter a market dominated by Cambridge, Mass.-based Genzyme Corp.'s Cerezyme (imiglucerase) - the ... -BioWorld Online

Research and Markets: Genzyme's Inorganic Growth Path and ...  Aug 3, 2006
Genzyme's revenue increased at a CAGR of 30.87% over 2001-04. This was primarily on account of Renagel, Fabrazyme and Cerezyme sales. ... -Business Wire

Genzyme cleared for additional manufacturing in Ireland  Jul 25, 2006
...location. Genzyme is also currently conducting approval-qualifying manufacturing runs of Cerezyme and Myozyme at the facility. Myozyme ... -Pharmaceutical Business Review

Alfimeprase to succeed Genentech's alteplase?  Aug 2, 2006
Genzyme of Cambridge, Massachusetts, pioneered enzyme therapy in the 1980s and 1990s, developing the first recombinant enzyme, Cerezyme (imiglucerase). ... -Nature.com (subscription)



Genzyme Launches Initiative to Assist the Development of ...  10 Apr 2006
Among the programs Genzyme sponsors is the Gaucher Initiative, a partnership with Project HOPE that brings Cerezyme® (imiglucerase for injection) therapy to ... - Yahoo! News

Genzyme Reports Financial Results for Fourth Quarter of 2005 and ...  Feb 15, 2006
Genzyme also recorded $16.9 million in charges for unsuccessful production runs of Cerezyme® that occurred as the company’s Allston Landing manufacturing ... - WebWire,

Genzyme Sticks With Forecast  Feb 15, 2006
Newer products will have an increasingly greater impact on the top line as they continue to grow, while Cerezyme sales in 2006 will represent 30% of its ... - TheStreet.com

Genzyme posts $2.7B in '05 sales  Feb 15, 2006
For example, the company's first major project, the enzyme replacement therapy Cerezyme, five years ago accounted for most of Genzyme's revenue. ... - Boston Business Journal,

Genzyme Reports 22 Percent Increase in Fourth-Quarter Revenue  Jan 9, 2006
Fourth-quarter sales of Cerezyme(R) (imiglucerase for injection) enzyme replacement therapy for Type 1 Gaucher disease were $232 million, 6 percent greater ... - MSN Money

Genzyme's Revenue Set to Climb  Jan 9, 2006
Analysts surveyed by Thomson First Call were expecting revenue of $729.9 million. Sales of one of its top drugs, Cerezyme, climbed 6% to $232 million. ... - TheStreet.com

Genzyme 4th-qtr revenue rises 22 pct on drug sales  Jan 9, 2006
Sales of Cerezyme, the company's treatment for Gaucher disease, a condition that causes enlargement of the liver and spleen, rose 6 percent to $232 million. ... - Reuters

S&P Cuts Alberto-Culver Shares to Hold from Buy  Jan 10, 2006
Renagel sales of $111 million are in line, $232 million Cerezyme sales were $9 million below our forecast, and $81 million Fabrazyme sales were $1 million below ... - BusinessWeek

Early numbers from Genzyme show 24% revenue rise  Jan 9, 2006
Its drug Cerezyme, designed to treat the enzyme disorder Gaucher disease, jumped to $933 million in sales in fiscal 2005, up from $839 million the year before. ... - Boston Business Journal

BioMarin Establishes Commercial Operations in Europe  Jan 10, 2006
...responsible for overseeing the development and implementation of reimbursement planning and launch for multiple products, including Cerezyme and Ceredase. ... - PR Newswire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional